Drug Discovery · San Diego, CA · Founded 2024 · Privately Held (backing)
Operator of a biotechnology research designed to create novel, easy-to-administer therapies for autoimmune diseases. Candid Therapeutics is based in San Diego, CA and was founded in 2024. It was valued at $657 million at its Series B in Aug 2024, the last priced event on record. It has raised $445 million across 1 recorded round; the latest was a $370 million Series B in Aug 2024.
PMV mark · valuation
$657.0M
Oct 2026
Priced at
its Series B
Aug 2024
Total raised
$445.0M
Last round
Early Stage VC (Series B)
Aug 2024
No prints on record
No secondary trades in Candid Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Candid Therapeutics stock.
